Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 3.45% 6.00 5.90 6.10 6.00 5.80 5.80 1,113,224 15:07:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 6.1 -0.0 0.1 75.0 27

Byotrol Share Discussion Threads

Showing 9501 to 9521 of 10675 messages
Chat Pages: Latest  391  390  389  388  387  386  385  384  383  382  381  380  Older
DateSubjectAuthorDiscuss
19/5/2020
22:01
Thanks Cassini. Interesting. Probably not short a few bob.
cumnor
19/5/2020
21:55
Vincent Paul Silvester, age 65, Guildford, Surrey. Non-exec Director with Elute Intelligence (software company) 2016 until Feb 2020 (resigned). Prior to that, with Seneca Asset Management in 2014 (one month!) and Seneca Asset Managers Ltd (2 months, concurrent with the Seneca Asset Management position) and also Midas Capital Management ltd (2 months, concurrent with the previous position, as Financial Director) and Bonnishott Ltd before that. Wife is Nuala Vincent.
cassini
19/5/2020
20:44
Anyone any further forward with who our newly announced 3% holder is?
mutley28
19/5/2020
12:23
LOL! Whoever they are, they've bought around £800,000 of shares now, so they're evidently convinced.... Https://www.investegate.co.uk/byotrol-plc--byot-/rns/holding-s--in-company/202005191208433666N/
rivaldo
19/5/2020
11:33
Suffering succotash
riddlerone
19/5/2020
11:14
Who is mr silvester?
the ghost who walks
18/5/2020
20:02
My understanding is the new EMA and FDA guidelines are coming in to place in the next year Or so this was prior to C19 Arriving and a large number of the current prodUcts will become obsolete as will not pass the new guidelines. In theory This should create a major opportunity and an escalation in licensing deals which we are starting to see or the potential for a take over by a larger player which was my original thought and investment strategy along with the growth potential. It’s clear that from your posts you have an in-depth knowledge of the past failings to some extent and I’m not convinced they have the strongest management team but I’m happy to have taken a position and feel everything is in place for a escalation in earnings going forward I may well be wrong
best1467
18/5/2020
19:06
Looking at the trades, that strong start, lots of buys, followed by lots of sells towards the end of the day... Trades: 2.46m buys v 2.37m sells almost as if people were rotating the trades.. ;-)
sikhthetech
18/5/2020
15:19
Best1467, No question about the product. How much will Byot earn from it though? The product is great in some environments but not in one's where it needs to be cleaned after every event, ie kitchens after cooking, hospitals after operations etc.. How many repeat orders have they had? Advanced Hygienics (AH) has been a partner for THREE yrs. Have they had meaningful royalties over the last 3 yrs? Royalties from an established deal would give a rough idea as to what can be expected. Was it £millions then? Whatever happened to Rentokil, Synergy and all the other deals? The Mcap is around £25m and fy2021 revenues of £9m(Finncap) - is the potential already in the price?
sikhthetech
18/5/2020
15:06
RI has paid to Byotrol an initial license fee of US$250k (Win) and will pay a quarterly royalty payment based on product sales (Win) (with material minimum annual guaranteed payments) thereafter. Subsequent to this deal, Byotrol will no longer incur material costs in the US (Win). I love this part of that recent RNS Game changer for BYOT Win Win Win
techair
18/5/2020
14:24
I don’t see how anyone doubt the quality of the Ip it’s the main value and growth driver Tristel CEO spoke in glowing Reference to the Tech and in the future it will continue to be a growth driver going forward. Reference to the USA deal making a takeover less likely that was the other main reason I invested but the are keeping the rights to the IP in the states so while it is less likely it’s still a possibility
best1467
18/5/2020
14:16
Tick as you are filtered I cannot and will not read what you are saying but all I can say is keep doing it as its priceless for the shareprice
riddlerone
18/5/2020
13:41
I think the success or otherwise of a product depends on whether they get repeat orders... 1st orders don't really say much about a product as many will simply try it. If customers repeat their orders then it can been seen as a winner.. I'd say a serious player would look at repeat orders. If you look at Target site, most of the reviews were from those who received free samples, so no evidence of new customers with repeat orders... https://www.target.com/p/byotrol24-lavender-morning-disinfectant-cleaner-plus-24-hour-surface-sanitizer-25-fl-oz/-/A-76150265
sikhthetech
18/5/2020
13:39
who spent 35 coins today hiding a post STT?Totally still paying a divi with that 55p placing that screwed there shareholders
football
18/5/2020
13:33
Brownson, Good point. I think any major company would look for a company which can demonstrate a history of progressive deal making...including being able to retain those deals. Otherwise it becomes a speculative punt based on Covid19. A lot of the revenue is dependant on Covid19, which is more of a short term bet... They have signed many deals in the past, so where have they all gone... and whatever happened to all those deals, some global, following the Swine flu pandanmic when they were also confident of the prospects for Byotrol????.. "The significant increase in sales is in part due to the concern regarding swine flu; however it can also be attributed to a greater appreciation of the qualities, efficacy and broad applications of Byotrol. " "We remain confident of the prospects for Byotrol " Distributors & Parners " Healthcare through our relationship with Synergy Health plc in Europe and through distributors in the US * Food and beverage, both through distributors and direct sales * Consumer products through our joint venture, Byotrol Consumer Products Ltd. " https://uk.advfn.com/stock-market/london/byotrol-BYOT/share-news/Interim-Results/40388101
sikhthetech
18/5/2020
07:46
I'd be interested to know whether people think the recent deals make them more, or less attractive for a takeover. My feeling is they are less attractive to a major player but maybe more attractive to a punter with money
brownson
18/5/2020
07:37
It surely can`t avoid being bought. It`s so cheap, in the right sector etc etc
arcadian
18/5/2020
07:06
All right. I'll say it then. Seems like a strong start!
1gw
17/5/2020
18:48
Riddleone, "So EK has a price of 10p which values byotrol at £40M.So the question is What profit for 2020/21 £1m." £40m mcap!!! Byot made £250k on revenues of £6m. They MIGHT make £1m profit. If you think they are cheap £40m on a possible £1m profit in a YEAR's time then have a look at TLY... These figures are for fy2020, March, results due July. not speculation on what might happen over the next year.. TLY: Recent TU suggest £3.5-£4m ebitda on £100-£120m revenues.. and they have £9m cash... EBITDA ~£3.5m-£4m - AHEAD of expectations of £3.4m Revenue ~£100m-£120m, below expectations of £120m Cash: £8.9m paying dividends (they paid an interim divi... the final, depending on feelings around covid19 and supporting the NHS.) Mcap £35m!!!!
sikhthetech
17/5/2020
15:07
1gw, Finncap are indeed behind the curve, there is zero chance of £9m in FY21. Worst case scenario that H2 reverts to prior year H2 run rates is £4m add in £6m for H1 already gets you to £10m. Covid impact is worth £1m incremental revenue per quarter so £11m feels prudent but if trading continues in line with Q1 for the remainder of the year thats £12m easily. This is all underlying business and zero upfront payments for licensing. So i use £11m. Maintain cost of sales at 40% of income, grow sales and marketing costs in line with revenue growth, 50% R&D increase, maintain other admin costs flat vs prior year and extend the depreciation and amortisation profile. Gets us to £2m clean PBT. With £416m shares i arrive at a Forward PE of 13. Price target of 9p is a nice round PE of 20. The good news is that i take no account of tax credits or savings/synergies from the medimark Acquisition. H2 is usually stronger than H1 which i have not factored in. I also assume zero US income in FY21, all i account for is the upfront license fee and no other one off licensing payments. Finccap with sharpen their pencils after the interim results IMO. £9m is simply Q1 actuals outperformance and Q2-Q4 in line with H2 prior year run rates. Lazy. Sickinthehead - you are welcome
rimau1
17/5/2020
14:25
1gw "Personally I think finnCap are somewhat behind the curve now. " What's wrong with just taking a position and waiting to see how it plays out? Why try so hard to persuade others into buying off the back of dubious speculation? Is it just so you can get out on an artificial spike and onto the next big thing? As to Royalties, after being pressed on your "£m" misrepresentation, you've admitted that Solway's is "£300k" and not millions Your comment #5977: "Solvay Actizone is £0.3m (the payment received on 2nd April) plus the final guaranteed payment due under that agreement for this year. These cash payments from Solvay have already been booked as revenue (as I understand it) on a discounted basis so there will be little or no revenue contribution from the Solvay minimum guaranteed payment(s), but there will be cashflow." You claim to have spoken to the Board about US partnerships but won't answer the simple question. Advanced Hygienics (AH) has been a partner for THREE yrs. Have they had meaningful royalties over the last 3 yrs? Royalties from an established deal would give a rough idea as to what can be expected. Was it £millions then?
sikhthetech
Chat Pages: Latest  391  390  389  388  387  386  385  384  383  382  381  380  Older
ADVFN Advertorial
Your Recent History
LSE
BYOT
Byotrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201128 02:58:23